Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Gilead Sciences completes acquisition of Kite Pharma
On August 28, 2017, Gilead and Kite announced that Kite, Gilead and Purchaser had signed a definitive merger agreement pursuant to which a tender offer would be made.
On August 28, 2017, Gilead and Kite announced that Kite, Gilead and Purchaser had signed a definitive merger agreement pursuant to which a tender offer would be made.
Endocyte intends to move quickly into Phase 3 development of 1 Lu-PSMA-617, a radioligand therapeutic (RLT) that targets the prostate-specific membrane antigen (PSMA), present in approximately 80% of
Hundreds of thousands of Americans could be protected from or treated for Ebola infections through the first purchase of vaccines and therapeutic drugs by the Biomedical Advanced Research
The FDA’s decision on approval is anticipated to be taken by 28 January 2018. Roche’s supplemental Biologics License Application (sBLA), which was accepted by the FDA, is based
This decision was made based on a review of available Phase 2 efficacy data and in consideration of the evolving marketplace and the growing number of treatment options
"Novartis pioneers new therapeutic paradigms, creating definitive medicines for life-threatening diseases," said Jay Bradner, President of the Novartis Institutes for BioMedical Research. "Our Berkeley alliance powerfully extends our
Tricida plans to report topline results from this study in the second quarter of 2018. If successful, TRCA-301 will serve as the pivotal trial for the submission of
“This alliance aims to define patients with solid tumors who may benefit from immunotherapy and to develop therapy resistance strategies,” said Aung Naing, M.D., associate professor of Investigational
Jacobs was selected for this project phase following the successful completion of the conceptual study and basic engineering design As Ferring Pharmaceuticals’ principal biopharmaceutical product development center, this
Bevespi Aerosphere showed a significant improvement in lung function as measured by trough forced expiratory volume in one second (FEV1), compared to its monotherapy components (glycopyrronium 14.4 µg